by 30 Technology | Feb 22, 2021 | News
30 Technology enters into a strategic Licencing Agreement to develop new treatments for multi-drug resistant tuberculosis Thirty Technology joins the fight against antibiotic resistant infection. London, UK, 22 February 2021. Thirty Holdings Limited (“30 Technology”)...
by 30 Technology | Feb 19, 2021 | News
30 Technology launches a critical clinical trial of RESP301 in cystic fibrosis patients with serious lung infections RESP301 to combat antibiotic resistant/refractory infection in people with cystic fibrosis London, UK, 19 February 2021. Thirty Respiratory (“30...
Recent Comments